Lyell Immunopharma Raises $425 million IPO
Lyell Immunopharma raised $425M in IPO financing led by Various, with participation from Various (IPO). T cell therapy for solid tumors. The new capital is framed around Complete Phase 1 trials for LYL797 and LYL845 T cell programs.
What it does
T cell therapy for solid tumors. The business sits in Healthcare & Life Sciences, where funded companies are using fresh capital to deepen product coverage, distribution, or operating capacity.
Traction
AI-designed T cells maintain efficacy in solid tumors where CAR-T fails. Management framed the new capital around Complete Phase 1 trials for LYL797 and LYL845 T cell programs.
Trend impact
Solid tumor T cell therapy competing with Kite and Bristol Myers Squibb. The capital raise matters because it gives the company more room to compete for customers, talent, and mindshare while incumbents and adjacent startups respond with clearer product depth or distribution.
Funding history
- June 1, 2021 · IPO · $425 million · Various (IPO)
- June 1, 2022 · Growth Round · $100 million · Various
Products & services
- Healthcare & Life Sciences workflow monitoring tied to the funding announcement
- Customer-facing product described on the company website
- Operational tooling for healthcare & life sciences teams
- Data capture and reporting across core business processes
- Team expansion support funded by the latest round